INT167847

From wiki-pain
Revision as of 23:26, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2002
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 3.02
Pain Relevance 1.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Chrna7) plasma membrane (Chrna7) cytoplasm (Chrna7)
Chrna7 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Botox 69 100.00 Very High Very High Very High
member 8 1 97.96 Very High Very High Very High
Piles 23 92.40 High High
long-term potentiation 78 82.12 Quite High
Potency 3 82.00 Quite High
depression 72 81.48 Quite High
Pain 30 74.40 Quite High
Angina 7 67.92 Quite High
Inflammation 9 67.64 Quite High
fibrosis 1 22.48 Low Low
Disease Link Frequency Relevance Heat
Convulsion 1 99.24 Very High Very High Very High
Cognitive Disorder 1 98.44 Very High Very High Very High
Muscular Spasm 4 97.28 Very High Very High Very High
Anorectal Disorders 25 92.40 High High
Muscle Hypotonia 2 91.00 High High
Dysphagia 34 87.44 High High
Epilepsy 1 87.08 High High
Disease 5 86.64 High High
Depression 72 81.48 Quite High
Clostridium Infection 4 78.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The best characterized toxins are botulinum toxin type A (BTXA) and botulinum toxin type B (BTXB), both used therapeutically and commercially available.[12]

BTX: THE MOLECULAR MODE OF ACTION [FIGURE 1]

Positive_regulation (botulinum toxin type B) of Gene_expression (type) of BTX associated with botox
1) Confidence 0.49 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.27 Pain Relevance 0.24
The best characterized toxins are botulinum toxin type A (BTXA) and botulinum toxin type B (BTXB), both used therapeutically and commercially available.[12]

BTX: THE MOLECULAR MODE OF ACTION [FIGURE 1]

Positive_regulation (botulinum toxin type B) of Gene_expression (type) of BTX associated with botox
2) Confidence 0.49 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.27 Pain Relevance 0.24
Indeed, sphincter manometry after BTX injection has demonstrated a lowering of resting intranal pressure.[6]

SELECTION OF PATIENTS

Positive_regulation (demonstrated) of Gene_expression (injection) of BTX
3) Confidence 0.40 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840903 Disease Relevance 0.91 Pain Relevance 0.29
The best characterized toxins are botulinum toxin type A (BTXA) and botulinum toxin type B (BTXB), both used therapeutically and commercially available.[12]

BTX: THE MOLECULAR MODE OF ACTION [FIGURE 1]

Positive_regulation (botulinum toxin type B) of Gene_expression (type) of BTX associated with botox
4) Confidence 0.37 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.27 Pain Relevance 0.24
Absence of the Transient Receptor Potential Cation Channel, Subfamily M, Member 1 (TRPM1) gene product is proposed as a possible mechanism for the severe visual impairment; absence of CHRNA7 (alpha7-nicotinic receptor subunit) as a cause of the refractory seizures and severe cognitive impairment; and deletion of MTMR10 and/or MTMR15 (encoding myotubularin related proteins) alone or combined with other homozygously deleted genes as a cause for the congenital hypotonia with areflexia.
Positive_regulation (cause) of Neg (absence) Gene_expression (absence) of CHRNA7 associated with cognitive disorder, muscle hypotonia, convulsion and member 8
5) Confidence 0.27 Published 2010 Journal Am. J. Med. Genet. A Section Abstract Doc Link 20425840 Disease Relevance 0.46 Pain Relevance 0.10
Annese et al. reported on two patients with prior myotomy and three patients with prior dilatation who responded well to BTX injection when the global symptom score and LOS pressure were evaluated after 1 month and 6 months.
Positive_regulation (responded) of Gene_expression (injection) of BTX
6) Confidence 0.25 Published 2002 Journal BMC Gastroenterol Section Body Doc Link PMC122056 Disease Relevance 0.55 Pain Relevance 0.07
Results in patients before and after BTX treatment
Positive_regulation (after) of Gene_expression (treatment) of BTX
7) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.14 Pain Relevance 0.19
BTX treatment caused no significant changes in the BRS (baseline: 13±5.2 points; week 1: 13±4.0 points; week 2: 12.1±4.2 points; week 4: 10.7±4.6 points) or in the BDS (baseline: 67.7±27.2%; week 1: 64.6±25.2%; week 2: 63.8±26.3%; week 4: 71.9±15.7%) but a trend for a decrease in blink rate (F 3; 21?
Neg (no) Positive_regulation (caused) of Gene_expression (treatment) of BTX
8) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964285 Disease Relevance 0.15 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox